New York, US – October 06, 2025 –The Insight Partners has published a new, comprehensive report, titled “Allergy Immunotherapies Market Share, Size, Trends, and Forecast by 2031.” This report underscores the rapid advancements driven by FDA approvals, pioneering pediatric trials, and disease-modifying treatments. Together, these factors are transforming the landscape of allergy care across respiratory, food, and venom allergy segments.

Pediatric Focus and Disease-Modifying Treatments

The ongoing Allergy Immunotherapies Market growth is largely influenced by significant clinical breakthroughs and the increasing emphasis on pediatric immunotherapy solutions. The adoption of personalized dosing and novel delivery methods, such as sublingual tablets and epicutaneous patches, is reshaping patient care and expanding the market size.

• ALK’s recent data shared at EAACI 2025 spotlighted pediatric sublingual immunotherapy tablets and a nasal adrenaline spray, marking important strides in childhood allergy management. The peanut SLIT-tablet demonstrated both safety and long-term efficacy, signaling its rising prominence within the allergy immunotherapy field.
• Nestlé Health Science continues to be a dominant force in the Allergy Immunotherapies Market share with Palforzia®, the first FDA-approved treatment for peanut allergies in children. Their collaboration with Enterome on microbiome-based therapies, named AllerMimics™, illustrates innovative efforts to target peanut allergens with precision medicine approaches.
• The success of Stallergenes Greer’s Phase III STAGR320 trial for house dust mite-induced allergic rhinitis is notable, achieving its primary endpoints by significantly improving symptoms and quality of life across a wide patient base. This outcome reinforces Stallergenes Greer’s position as a key contributor to the expanding market and highlights important market trends focused on improving patient experiences.
• HAL Allergy’s recent CEO appointment, Dr. Philip Boehme, emphasizes the company’s strengthened focus on broadening its allergen immunotherapy portfolio. With ongoing research into respiratory and food allergy treatments—including therapies targeting peanuts and tree nuts—HAL Allergy is poised to increase its market share and influence.
• DBV Technologies presented compelling three-year data from its EPITOPE Phase 3 trial for the Viaskin® Peanut patch. The findings revealed sustained immunological improvements in toddlers without serious adverse reactions, underscoring the growing interest in epicutaneous immunotherapy and its potential to revolutionize pediatric allergy care.

Meanwhile, Allergy Therapeutics has made remarkable progress with its Grass MATA MPL Phase III trial and has advanced dosing in its VLP Peanut vaccine trial, signaling sustained momentum in food allergy immunotherapy innovations.

Get Free Sample- https://www.theinsightpartners.com/sample/TIPRE00008219

Market Developments and Industry Milestones

Key players continue to redefine the allergy immunotherapy space with new product launches, clinical trial results, and regulatory advances:

• ALK’s nasal adrenaline spray demonstrated comparable efficacy to traditional injections, enhancing emergency allergy care options.
• Nestlé’s Palforzia extends its reach globally, complemented by novel microbiome-based treatments under development.
• Stallergenes Greer advances regulatory submissions following successful STAGR320 trial outcomes.
• HAL Allergy accelerates R&D efforts under new leadership, expanding its pipeline for respiratory and food allergies.
• DBV Technologies prepares for a Biologics License Application (BLA) submission for Viaskin Peanut.
• Allergy Therapeutics collaborates with prestigious academic centers to fast-track its VLP Peanut vaccine.

These strategic moves reinforce the dynamic nature of the Allergy Immunotherapies Market analysis, highlighting innovation and regulatory compliance as key drivers of competitive advantage.

Leading Players and Competitive Landscape

The growth trajectory of the Allergy Immunotherapies Market size is defined by major pharmaceutical companies and biotech firms focused on delivering targeted, effective, and patient-friendly immunotherapies. The adoption of sublingual tablets and epicutaneous patches across healthcare and retail channels is improving treatment accessibility and adherence.

According to a research leader from The Insight Partners, “The Allergy Immunotherapies Market is entering an era where precision, safety, and long-term disease modification shape treatment protocols. These advances are transforming allergy management from mere symptom relief to durable immunological change.”

Notable companies at the forefront include:

• ALK-Abelló A/S
• Nestlé Health Science
• LETIPharma
• Stallergenes Greer
• HAL Allergy B.V.
• Johnson & Johnson Services, Inc.
• Anergis
• DBV Technologies
• Dermapharm Holding
• Allergy Therapeutics

Market Outlook and Future Projections

The Allergy Immunotherapies Market forecast anticipates steady growth driven by increased demand for safe, effective allergy treatments worldwide, especially in pediatric populations. The expanding market size reflects rising awareness and adoption of immunotherapies that deliver long-term relief and improved quality of life.

Companies with strong market share and investment in novel pediatric and disease-modifying therapies are positioned to lead the next generation of allergy care innovations. Continuous technological progress coupled with patient-centric development strategies will further accelerate this expansion.

Expert Insights from The Insight Partners

“The ongoing Allergy Immunotherapies Market growth is primarily driven by the need for targeted, safe, and disease-modifying allergy treatments,” said a spokesperson from The Insight Partners. “Our comprehensive report equips pharmaceutical developers, healthcare providers, and investors with the insights required to capitalize on emerging trends and opportunities.”

About The Insight Partners

The Insight Partners delivers in-depth syndicated and customized market research across healthcare, technology, and industrial sectors. Known for its actionable insights and strategic intelligence, the company helps businesses stay competitive in dynamic global markets.

Contact Us

Email: sales@theinsightpartners.com
Website: www.theinsightpartners.com
Phone: +1-646-491-9876